· 2 min read
NSF Expands Health Sciences Group With Acquisition of Majority Interest in Amarex CRO
ANN ARBOR, Mich. - Global public health organization NSF has acquired a majority interest in Amarex Clinical Research, LLC, a clinical stage contract research organization (CRO) headquartered in Germantown, Maryland. The transaction supports NSF’s mission of protecting and improving human health through expanded consulting services to the medical device and pharma/biotech industries. As part of NSF’s global health science consulting business, the highly-respected CRO will be known as Amarex Clinical Research, LLC, an NSF company.
Amarex Clinical Research, LLC will gain access to NSF’s expert network and international scope. As part of NSF’s global network of locations, Amarex will continue to operate from its U.S. office near Washington, D.C. The company also operates an office in Taiwan and has a developing presence in Europe.
“NSF plays an important role in the pharmaceutical and biotech industry as a champion of quality, scientific rigor and best practices aimed at protecting and improving human health. Together with Amarex, we are creating a single source for integrated, expert health science consulting services across the entire product lifecycle,” said NSF President and CEO Kevan Lawlor. “Amarex brings clinical trial expertise to NSF’s large base of training, quality and consulting clients, and Amarex’s CRO clients may now benefit from NSF’s global reach and expertise in European Union Qualified Person and Medical Device Regulation training, chemistry manufacturing and controls support, and supplement testing inspection and certification.”
“Amarex is excited to join the NSF family. Amarex will be able to leverage NSF’s global infrastructure to expand our contract research capabilities and better serve clients with the design and execution of clinical trials and navigating the FDA, TFDA and EMA regulatory approval process,” said Amarex founder Dr. Kazem Kazempour, who will continue as president and CEO of Amarex, an NSF company. “NSF’s operational excellence will accelerate our expert team’s leap forward in the CRO market, and better help pharmaceutical, biotech and medical device/diagnostic companies develop products and services that will protect and improve human health while minimizing inefficiencies to save time and reduce unnecessary costs.”
Since 1998, Amarex Clinical Research has been helping biotech, medical device and pharmaceutical companies conduct scientifically sound clinical trials and navigate complex regulatory environments in a wide range of therapeutic indications, including oncology, central nervous system, wound healing, infectious disease, cardiovascular and urology.
As part of NSF, Amarex will support companies with regulatory affairs, project/trial management, clinical operations, biostatistics, data management, pharmacovigilance, data monitoring committees, medical writing and consulting.
For media inquiries, please contact Thomas Frey at email@example.com or +1-734-214-6242.
In 2019, NSF is celebrating 75 years of protecting and improving human health. The global public health organization facilitates standards development, and tests and certifies products for the food, water, health sciences and consumer goods sectors to minimize adverse health effects and protect the environment. Founded in 1944, NSF is committed to protecting human health and safety worldwide. NSF is a Pan American Health Organization/World Health Organization (WHO) Collaborating Center on Food Safety, Water Quality and Indoor Environment.
NSF’s health sciences services include training and education, consulting, regulatory guidance, corporate compliance and, separately, auditing, DNA testing, certification and R&D for the pharma biotech, medical device and dietary supplement industries throughout the product lifecycle. NSF facilitated the development of the only American National Standard (NSF/ANSI 173) that verifies the health and safety of dietary supplements and also tests and certifies products to this standard.